Microgynon 20

Ethinylestradiol, the active ingredient in Microgynon 20, is a combined oral contraceptive presented as a 20 µg ethinylestradiol / 100 µg levonorgestrel oral tablet for oral use. It prevents pregnancy by inhibiting ovulation and altering cervical mucus and endometrial lining in women of reproductive age.

GNH USA supplies Microgynon 20 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Microgynon 20, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.

Contraception: provides reliable prevention of pregnancy for women of reproductive age. Menstrual cycle regulation: helps achieve more predictable bleeding patterns when taken continuously. Acne management: may improve moderate acne in women as a secondary therapeutic benefit.

Adverse reactions may occur with any hormonal contraceptive.

Common Side Effects: - Nausea: mild stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Irregular bleeding: spotting or breakthrough bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein clot formation. - Stroke: cerebrovascular accident, especially in high‑risk individuals. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Use of Microgynon 20 requires careful assessment of individual risk factors.

Contraindicated in pregnancy: product is Category X and must not be used by pregnant women. Avoid in history of thromboembolic disorders: increased risk of clot formation. Screen for hypertension: use with caution if blood pressure exceeds 140/90 mmHg. Do not use in smokers over age 35: heightened cardiovascular risk. Monitor liver function: contraindicated in severe hepatic impairment. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and light.

Microgynon 20 may have clinically significant drug interactions.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): reduce contraceptive effectiveness. - Rifampin and other rifamycins: lower hormone levels, increasing risk of unintended pregnancy. - Protease inhibitor antiretrovirals (e.g., ritonavir): may raise hormone concentrations, heightening side‑effect risk.

Moderate Interactions (Monitor Closely): - St. John’s wort: may diminish contraceptive efficacy. - Certain antibiotics (e.g., tetracycline): possible reduction in effectiveness. - SSRIs (e.g., fluoxetine): may increase plasma hormone levels.